查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586208

頭孢菌素藥物市場：按頭孢菌素的世代、藥物管理、處方類型和應用分類 - 全球預測 2025-2030

Cephalosporin Drugs Market by Generation of Cephalosporin (Fifth-Generation, First-Generation, Fourth-Generation), Drug Administration (Injection, Oral), Prescription Type, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年頭孢菌素類藥物市值為113.7億美元，預計2024年將達到121.1億美元，複合年成長率為6.66%，預計2030年將達到178.6億美元。

頭孢菌素藥物是一類主要的 BETA-內醯胺抗生素，對於治療多種細菌感染疾病至關重要。該系列跨越多代，每代都具有不同的抗菌特性和臨床應用。這些藥物對於抵抗呼吸道感染疾病、皮膚感染疾病和尿道感染感染疾病至關重要，因此在醫院和門診環境中都至關重要。細菌感染疾病流行率的上升和抗生素抗藥性菌株的不斷出現凸顯了對頭孢菌素市場的需求。新興醫療保健領域不斷成長的需求以及手術預防中程序採用的增加證實了頭孢菌素的重要應用範圍。影響市場的關鍵發展因素包括藥物研發的進步、下一代頭孢菌素的強大管道以及新興國家醫療保健支出的增加。開發針對多重抗藥性細菌的新製劑以及擴大頭孢菌素在獸藥中的使用存在潛在機會，反映了醫療必要性和市場需求的融合。然而，該市場面臨嚴格的法律規範、潛在的副作用以及頭孢菌素抗藥性細菌增加等限制，需要市場相關人員謹慎引導。高研發成本和其他抗生素類別的競爭等競爭因素也成為擴張的障礙。業務成長的創新領域包括提高藥物療效，同時最大限度地減少副作用，以及透過開發新化合物和聯合治療來解決抗藥性細菌問題。注重製藥公司和學術機構之間的合作可以在這些領域取得突破。競爭激烈的頭孢菌素市場需要在研發和地理擴張方面進行策略性投資，以開拓未滿足的臨床需求，特別是在新興市場。總體而言，市場的性質需要敏捷性和創新，以適應全球醫療保健優先事項和抗生素抗藥性的演變。

主要市場統計
基準年[2023] 113.7億美元
預測年份 [2024] 121.1億美元
預測年份 [2030] 178.6億美元
複合年成長率（%） 6.66%

市場動態：揭示快速發展的頭孢菌素藥物市場的關鍵市場洞察

供需的動態交互作用正在改變頭孢菌素藥品市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 皮膚和尿道結石等細菌感染病例增加
    • 持續關注研究、開發和臨床試驗
    • 聯合治療的普及
  • 市場限制因素
    • 與頭孢菌素相關的副作用
  • 市場機會
    • 藥企、協會加大投入，加速抗生素藥物研發
    • 有利於抗生素藥物的政府法規修正案
  • 市場挑戰
    • 由於人們意識有限，農村和偏遠地區的供需失衡

波特五力：駕馭頭孢菌素藥品市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解頭孢菌素類藥物市場的外部影響

外部宏觀環境因素在塑造頭孢菌素藥品市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解頭孢類藥物市場競爭格局

對頭孢菌素藥品市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣頭孢菌素藥品市場供應商的績效評估

FPNV 定位矩陣是評估頭孢菌素藥品市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製頭孢菌素藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，頭孢菌素藥品市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 皮膚感染疾病和尿道感染等細菌感染疾病增加
      • 持續關注研發和臨床試驗
      • 聯合治療的廣泛應用
    • 抑制因素
      • 與頭孢菌素相關的副作用
    • 機會
      • 藥廠和協會加大投入，加速抗生素研發
      • 支持抗生素藥物的政府法規修正案
    • 任務
      • 農村和邊遠地區公眾認知度低，供需失衡
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 頭孢藥品市場 頭孢世代

  • 第五代
  • 第一代
  • 第四代
  • 第二代
  • 第三代

第7章 藥品監督管理部門的頭孢類藥品市場

  • 注射
  • 口服

第8章 頭孢類藥物市場（依處方箋型）

  • 非處方藥
  • 處方藥

第9章 頭孢菌素藥品市場：依應用分類

  • 耳部感染疾病
  • 呼吸道感染疾病
  • 皮膚感染疾病
  • 尿道感染

第10章 美洲頭孢菌素藥品市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區頭孢類藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲頭孢類藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Aristo Pharmaceuticals Ltd.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer AG
  • Covalent Laboratories Private Limited
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd
  • Novartis International AG
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-433AB1DC28F3

The Cephalosporin Drugs Market was valued at USD 11.37 billion in 2023, expected to reach USD 12.11 billion in 2024, and is projected to grow at a CAGR of 6.66%, to USD 17.86 billion by 2030.

Cephalosporin drugs, a major class of beta-lactam antibiotics, are pivotal in treating a broad spectrum of bacterial infections. Their scope spans multiple generations, each characterized by distinct antibacterial properties and clinical applications. These drugs are vital in combating infections such as respiratory tract infections, skin infections, and urinary tract infections, making them essential in both hospital and ambulatory settings. The cephalosporin market's necessity is underscored by the rising prevalence of bacterial infections and the continual emergence of antibiotic-resistant strains. The increasing demand from emerging healthcare sectors and the growing procedural adoption in surgical prophylaxis underscore their vital application scope. Key growth factors influencing the market include advancing pharmaceutical R&D, a robust pipeline for next-generation cephalosporins, and rising healthcare spending in developing regions. Potential opportunities lie in developing novel formulations targeting multi-drug resistant bacteria and expanding cephalosporin applications in veterinary medicine, reflecting a convergence between medical necessity and market demand. However, the market faces limitations including stringent regulatory frameworks, potential adverse effects, and the increasing prevalence of cephalosporin-resistant bacteria, necessitating careful navigation by market players. Challenging factors such as the high cost of R&D and competition from other antibiotic classes also pose barriers to expansive growth. For business growth, innovation areas include enhancing drug efficacy while minimizing side effects and addressing resistance through novel compound development and combination therapies. An emphasis on collaborations among pharmaceutical companies and academic institutions can generate breakthroughs in these areas. The cephalosporin market is competitive, necessitating strategic investments in R&D and geographical expansion to tap into unmet clinical needs, particularly in emerging markets. Overall, the nature of the market demands agility and innovations that align with global healthcare priorities and the evolving landscape of antibiotic resistance.

KEY MARKET STATISTICS
Base Year [2023] USD 11.37 billion
Estimated Year [2024] USD 12.11 billion
Forecast Year [2030] USD 17.86 billion
CAGR (%) 6.66%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cephalosporin Drugs Market

The Cephalosporin Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing cases of bacterial infection such as skin and UTIs
    • Continuous focus on R&D and clinical trials
    • Widespread application of a combination therapy
  • Market Restraints
    • Side effects related to cephalosporins drugs
  • Market Opportunities
    • Increasing investment by pharmaceutical companies & associations to boost the antibiotic drug development
    • Revised government regulation in favor of antibiotic drugs
  • Market Challenges
    • Limited consciousness among the people and unbalanced demand & supply in rural or remote areas

Porter's Five Forces: A Strategic Tool for Navigating the Cephalosporin Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cephalosporin Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cephalosporin Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cephalosporin Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cephalosporin Drugs Market

A detailed market share analysis in the Cephalosporin Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cephalosporin Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cephalosporin Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cephalosporin Drugs Market

A strategic analysis of the Cephalosporin Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cephalosporin Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Aristo Pharmaceuticals Ltd., AstraZeneca PLC, Baxter International, Inc., Bayer AG, Covalent Laboratories Private Limited, Eli Lilly and Company, GlaxoSmithKline Plc, Lupin Limited, Macleods Pharmaceuticals Ltd, Novartis International AG, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cephalosporin Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Generation of Cephalosporin, market is studied across Fifth-Generation, First-Generation, Fourth-Generation, Second-Generation, and Third-Generation.
  • Based on Drug Administration, market is studied across Injection and Oral.
  • Based on Prescription Type, market is studied across OTC Drugs and Prescription Drugs.
  • Based on Application, market is studied across Ear Infection, Respiratory Tract Infection, Skin Infection, and Urinary Tract Infection.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing cases of bacterial infection such as skin and UTIs
      • 5.1.1.2. Continuous focus on R&D and clinical trials
      • 5.1.1.3. Widespread application of a combination therapy
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects related to cephalosporins drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment by pharmaceutical companies & associations to boost the antibiotic drug development
      • 5.1.3.2. Revised government regulation in favor of antibiotic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Limited consciousness among the people and unbalanced demand & supply in rural or remote areas
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cephalosporin Drugs Market, by Generation of Cephalosporin

  • 6.1. Introduction
  • 6.2. Fifth-Generation
  • 6.3. First-Generation
  • 6.4. Fourth-Generation
  • 6.5. Second-Generation
  • 6.6. Third-Generation

7. Cephalosporin Drugs Market, by Drug Administration

  • 7.1. Introduction
  • 7.2. Injection
  • 7.3. Oral

8. Cephalosporin Drugs Market, by Prescription Type

  • 8.1. Introduction
  • 8.2. OTC Drugs
  • 8.3. Prescription Drugs

9. Cephalosporin Drugs Market, by Application

  • 9.1. Introduction
  • 9.2. Ear Infection
  • 9.3. Respiratory Tract Infection
  • 9.4. Skin Infection
  • 9.5. Urinary Tract Infection

10. Americas Cephalosporin Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cephalosporin Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cephalosporin Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Aristo Pharmaceuticals Ltd.
  • 4. AstraZeneca PLC
  • 5. Baxter International, Inc.
  • 6. Bayer AG
  • 7. Covalent Laboratories Private Limited
  • 8. Eli Lilly and Company
  • 9. GlaxoSmithKline Plc
  • 10. Lupin Limited
  • 11. Macleods Pharmaceuticals Ltd
  • 12. Novartis International AG
  • 13. Shionogi & Co., Ltd.
  • 14. Sun Pharmaceutical Industries Ltd.
  • 15. Taj Pharmaceuticals Limited
  • 16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CEPHALOSPORIN DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CEPHALOSPORIN DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CEPHALOSPORIN DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CEPHALOSPORIN DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OTC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY EAR INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023